[Federal Register Volume 65, Number 33 (Thursday, February 17, 2000)]
[Notices]
[Pages 8183-8184]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-3775]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Autotaxin: Motility 
Stimulating Protein Useful in Cancer Diagnosis and Therapy

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7 (a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive license to practice the inventions embodied in U.S. Patent 
Application S/N 07/822,043 entitled, ``Autotaxin: Motility Stimulating 
Protein Useful in Cancer Diagnosis'' filed on January 1, 1992 and now 
U.S. Patent 5,449,753 which issued on September 12, 1995; U.S. Patent 
Application S/N 08/346,455 entitled, ``Autotaxin: Motility Stimulating 
Protein Useful in Cancer Diagnosis and Therapy'' filed on November 11, 
1994 and now U.S. Patent 5,731,167 which issued on March 24, 1998; U.S. 
Patent Application S/N 08/977,221 entitled, ``Autotaxin: Motility 
Stimulating Protein Useful in Cancer Diagnosis and Therapy'' which was 
filed on November 24, 1997; and a U.S. Patent Application, NIH 
designation E-142-90/4, which is a continuing application based on U.S. 
Patent Application S/N 08/977,221, entitled, ``Autotaxin: Motility 
Stimulating Protein Useful in Cancer Diagnosis and Therapy'' to 
ZymoGenetics, Inc. of Seattle, Washington. The patent rights in these 
inventions have been assigned to the United States of America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to human therapeutics for the treatment 
of Type II diabetes and obesity.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before April 17, 
2000 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and 
other materials relating to the contemplated exclusive license should 
be directed to: Richard U. Rodriguez, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804. Telephone: 
(301) 496-7056, X287; Facsimile (301) 402-0220; E-mail [email protected].

SUPPLEMENTARY INFORMATION: U.S. Patent 5,449,753 claims various 
polypeptide sequences corresponding to human autotaxin as well as an 
autotaxin antibody which is suitable for immunohistochemistry. U.S. 
Patent 5,731,167 claims DNA segments encoding various polypeptide 
sequences corresponding to human autotaxin having immunogenic or 
biological activities; a recombinant DNA molecule comprising a vector 
and the DNA expressing autotaxin; and methods of producing and 
isolating recombinant autotaxin. U.S. Patent Application 08/977,221 and 
the continuation application based on it, have claims to various 
polypeptides corresponding to human autotaxin and relevant DNA 
sequences and vector claims for expressing, producing and isolating 
human autotaxin.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establish that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant

[[Page 8184]]

of the contemplated exclusive license. Comments and objections 
submitted to this notice will not be made available for public 
inspection and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: February 8, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-3775 Filed 2-16-00; 8:45 am]
BILLING CODE 4140-01-P